AbbVie announced results from a late stage clinical trial that found that its hepatitis C treatment proved to have 100% cure rates in patients.
AbbVie's Viekira Pak, which combines Viekirax and Exviera, proved effective without the need to combo with ribavirin.
According to AbbVie, GT1b patients with compensated liver cirrhosis achieved a 100 percent cure rate when Viekira Pak was administered to them as a standalone drug for up to 12 weeks.
Viekira Pak is a competitor product to Harvoni, Gilead Sciences' top-selling HCV drug.
Read the Bidness Etc story